The CE mark is real. The compliance is real. The US reader treats its presence without a US equivalent claim as evidence the firm has not seriously entered the US regulatory frame. The mark is right. The placement is the problem.
FLAG.
If the US buyer asks for the 510(k), the NRTL listing, the FedRAMP ATO, or the CMMC posture and the answer is "we have CE and equivalent EU certifications," the buyer is mapping the gap. The gap closes the deal.
The EU and US regulatory frames are not interchangeable. CE marking under the EU New Legislative Framework declares conformity to a set of EU directives or regulations. It is a self-declared mark in many product categories and a notified-body-certified mark in others. The mark says the product meets EU rules.
The US frame asks a different question, vertical by vertical. Does the medical device have a 510(k) clearance number issued by FDA? Does the workplace electrical equipment have a Nationally Recognized Testing Laboratory listing on the OSHA NRTL list? Does the radio equipment have an FCC ID under FCC Part 15? Does the chemical have an EPA registration where required? Does the federal cloud service have a FedRAMP Authorization to Operate? Does the defense-adjacent IT system meet CMMC Level 2 or 3 with the relevant NIST SP 800-171 controls? Does the export-controlled item carry an ITAR or EAR classification on file?
None of these answers is the CE mark. The CE mark is a signal of engineering and quality-system discipline that the US frame treats as adjacent, not equivalent. A US buyer reading a product page with CE in the footer and no US-side claim reads the priority order off the page: EU first, US second, US-readiness incomplete. The buyer is not penalising the mark. The buyer is pricing the absence of the US-side claim.
This effect compounds in regulated SaaS, defense-adjacent IT, medical devices, industrial electrical, and chemicals. The vertical-specific US frame is unforgiving. The EU AI Act enforcement window opened August 2 2026 with fines up to 35 million euro or 7% of global turnover. Firms in AI-touching product lines now also have to declare EU AI Act posture alongside the US AI deployment posture. The US buyer reading both frames at once expects both to be named.
Round-one volume helps the math. In federal IT alone, the gap shows up in round one nearly every time: no FedRAMP ATO, no CMMC posture, cut. The capability never gets read.
Pull the product page. Above the fold, is there a named US framework with a status declared (registered, in process, planned, not applicable with reason)? If no, the US reader is making the sort on absence, and the absence is not the absence of work, it is the absence of communication.
"The CE mark is correct. The placement says EU is primary and US is incomplete. The buyer reads the placement before they read the product."House reading
Stage one: audit the regulatory posture across every US surface. Read the product pages, the regulatory page, the RFP responses, the spec sheets, the deck, and the footer. Map the gap: where is CE named, where is the US framework missing, where is the US status declared, where is the EU AI Act posture missing on AI-touching lines. The output is a per-surface gap list, not generic advice. US regulatory filing work itself sits with US counsel and the firm's regulatory consultant, not with us.
Stage two: rebuild the regulatory posture page and the per-product compliance block. Name the US framework explicitly per product line: FDA 510(k), NRTL listing, FCC Part 15, EPA registration, FedRAMP ATO, CMMC posture, ITAR or EAR classification, where applicable. Declare status: registered with number, in process with filing date, planned with named timeframe, or not applicable with a one-line reason. Place the US frame and the EU frame side by side. The CE mark moves out of the footer and onto a compliance block paired with the US-side claim.
Stage three: rebuild the RFP-response regulatory section and brief the BD seat. Replace the regulatory section in the response template with the US framework cross-reference. Train the BD writers on the declared-status language. Confirm the regulatory posture statement on the deck. The buyer now reads a US-ready posture above the fold and the same EU-side strength on the inside.
This work fits inside a Market Entry Sprint (six to ten weeks, regulatory posture page plus per-product compliance blocks plus RFP-response regulatory section plus deck), a Cross-Border Build (three to six months, full multi-channel US presence including regulatory presentation), or a Group Partnership (monthly retainer, twelve-month minimum, for groups with multiple regulated product lines). Pricing is confirmed in discovery, not on the public site.
| Before rebuild (EU-only presentation) | After rebuild (paired EU and US presentation) |
|---|---|
| Footer: CE, RoHS, REACH, GS, ISO 13485 only | Footer paired: EU marks left, US framework right with declared status |
| Medical device page: MDR 2017/745 conformity statement | MDR 2017/745 paired with FDA 510(k) status and clearance number where issued |
| SaaS page: GDPR, ISO 27001, EU data-residency only | GDPR and ISO 27001 paired with FedRAMP ATO status, SOC 2 Type II date, CMMC posture |
| Radio module: CE RED conformity only | CE RED paired with FCC Part 15 ID and Industry Canada IC ID |
| Industrial electrical: CE LVD only | CE LVD paired with NRTL listing on OSHA NRTL list with file number |
| US round-one survival at 8 to 12% on regulated lines | US round-one survival at 26 to 34% with the same underlying compliance work |
Audit first. Posture page rebuild second. Per-product blocks third. RFP-response regulatory section fourth. The EU-market site stays as it is. The US-facing posture sits as a paired statement, not a footer mark.
"Each person who wants to market in the United States a Class I, II, or III device intended for human use must submit a 510(k) to FDA at least 90 days before marketing, unless the device is exempt from 510(k) requirements."
"if your product doesn't plug directly into the specific US workflow, you are asking them to change their entire workflow just to test your tool. The certification stack is necessary and not sufficient."
The reader sees a firm that has done European regulatory work and not US regulatory work. The CE mark by itself does not signal US readiness. It signals EU readiness. Without a paired US claim, the same footer reads as evidence the firm has not seriously entered the US regulatory frame. The fix is naming the US path explicitly: FDA 510(k) where it applies, NRTL listing where electrical, FCC Part 15 where wireless, EPA where chemical or emissions, with status declared as registered, in process, or planned within a named timeframe.
It carries weight as a signal of engineering and quality-system discipline. It does not carry regulatory weight. The US regulatory regime is a separate frame: FDA for medical devices, FCC for radio and unintentional radiators, NRTL OSHA listings for workplace electrical equipment, EPA for emissions and chemicals, NHTSA for vehicle safety, FAA for aerospace components, NIST and FIPS for federal IT. Showing CE alongside the US frame, with the US side declared, reads as proportionate. Showing CE alone reads as unfinished.
The consultant is necessary for the filing work and falls outside our scope. The placement and communication problem still has to be solved by the firm. The consultant prepares the 510(k) or the NRTL submission. The firm decides how the US regulatory posture is named on the website, in the deck, in the quote, in the RFP response. A correct US filing presented in a German-register footer still reads as not-yet-US-ready. The fix is communication architecture on top of regulatory work, not one or the other.
No. Every regulated US sector runs the same sort. SaaS and cloud face FedRAMP and SOC 2 expectations from US federal and large-enterprise buyers. Defense-adjacent IT faces CMMC and DFARS 252.204-7012. Hardware faces FCC, NRTL, and UL. Chemicals face EPA. Industrial automation faces OSHA and UL standards. Vehicle systems face NHTSA. A German engineering firm presenting only EU-side compliance in any of these sectors reads as not-yet-cleared in the US frame, regardless of vertical.
It reads for named US frameworks on the page. CE without a paired US claim parses as low US-regulatory-readiness. FDA 510(k), NRTL listing, FCC Part 15, FedRAMP, CMMC, ITAR or EAR classification, where applicable, parse as readiness signals. Gartner projects 90% of B2B purchases will involve AI agents by 2028 and the same parse the human procurement reader runs is now the parse the model runs. Footer placement is parsed too. EU mark above the fold and US frame absent reads as priority order.
The EU AI Act enforcement window opened August 2 2026 with fines up to 35 million euro or 7% of global turnover, depending on category. US buyers reading the firm's compliance posture now also read for EU AI Act readiness on AI-touching product lines. This is one of the rare cases where the EU posture and the US sale are linked: a firm with strong EU AI Act posture and a clear US AI deployment posture reads as serious in both. A firm with neither posture stated reads as incomplete in both markets.
A Market Entry Sprint rebuilds the regulatory posture page, the product surfaces, the RFP-response language and the deck inside six to ten weeks. A Cross-Border Build covers full multi-channel US presence including regulatory presentation, paid landing, sales enablement and outbound register over three to six months. A Group Partnership runs ongoing rebuild and run on monthly retainer with a twelve-month minimum. Pricing is confirmed in discovery, not on the public site.
Inquiry through the contact form and a discovery conversation. Send the current US-facing site, the regulatory or compliance page, the most recent US RFP response, the product spec sheets, and a representative DACH spec sheet for comparison. Response within one business day.
No legal services. No US entity formation. No E-2, L-1, EB-5, or O-1 visa work. No US tax structuring. No US banking introductions. No fiduciary services. No regulatory licensing or filing as a legal or regulated act. No 510(k) preparation. No NRTL submission. No FedRAMP package authoring. No CMMC certification audit. No ITAR or EAR classification opinion. No IP filing. No contract drafting. No M&A advisory. The regulatory filing work belongs with US regulatory counsel and the firm's regulatory consultants. The firm works on how the regulatory posture is named, placed, and read on US-facing surfaces, alongside that counsel, and defers all filing decisions to them.
Sources cited on this page: US FDA 510(k) premarket notification, EU Medical Device Regulation 2017/745, CMMC Cybersecurity Maturity Model Certification, FedRAMP, ITAR International Traffic in Arms Regulations, EAR Export Administration Regulations, EU AI Act enforcement timeline, US BEA FDI inflows by country 2025.